Descripción de la empresa
DBV Technologies S.A. operates as a clinical-stage biopharmaceutical entity dedicated to the research and development of epicutaneous immunotherapy products specifically within the French market. The company's primary asset is Viaskin Peanut, an immunotherapy solution that has successfully concluded its Phase 3 clinical trial for the treatment of peanut allergy. This enterprise functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself at the intersection of medical innovation and pharmaceutical regulation. With a market capitalization of $1.21B and annual revenue of $5.64M, the company maintains a significant valuation relative to its current top-line performance. The substantial disparity between the $1.21B market cap and the $5.64M revenue indicates that the market places a high premium on the company's future pipeline potential rather than current earnings generation. Although specific employee count data is not publicly disclosed in the available records, the organization's scale is defined by its asset-light development model typical of biotechnology firms. This structural characteristic allows the company to focus capital expenditure on R&D rather than extensive operational overhead, a common trait for clinical-stage entities seeking to advance their therapeutic candidates toward commercialization.
Salud financiera
The company reported a revenue of $5.64M over the trailing twelve months, yet recorded a net income of $-146,947,008, while EBITDA stood at $-143,862,000. The massive gap between the modest $5.64M revenue and the negative $146.9M net income reveals a cost structure dominated by high burn rates inherent in drug development and clinical trial expenses. Free cash flow is reported at $-64,285,000, which signifies that the company is consuming cash reserves to fund its operations and R&D efforts rather than generating liquidity from core business activities. Gross margin stands at 100.0%, a figure typical for biotechnology firms that have not yet incurred significant cost of goods sold relative to their sales volume in this development phase. In stark contrast, the operating margin is -6984.7% and the profit margin is 0.0%, illustrating that operating expenses vastly outweigh gross revenue. The company holds $194.17M in cash against $6.53M in debt, creating a robust liquidity buffer that supports its ongoing R&D initiatives. With a debt-to-equity ratio of 3.87, the balance sheet appears leveraged on paper, but the absolute debt level is negligible compared to the available cash reserves. The current ratio of 3.67 indicates strong short-term liquidity, suggesting the company can comfortably meet its short-term obligations with its current assets. Return on Equity is -149.8% and Return on Assets is -61.4%, metrics that reflect the temporary negative returns expected during the capital-intensive stages of product development before commercial revenue scales.
Evaluación de valoración
The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is listed as -78.07, implying that future earnings are projected to remain negative or that the metric is not yet meaningful for valuation purposes. The price-to-book ratio is 5.71, indicating that the market values the company at a significant premium over its book value, likely reflecting the intangible value of the intellectual property and the potential success of the Viaskin Peanut pipeline. The price-to-sales ratio is 214.84, a metric that suggests investors are pricing in substantial future growth expectations despite the current low sales figure. Additionally, the EV/EBITDA stands at -32.19, which further underscores that traditional earnings-based valuation models are not applicable at this stage of the company's lifecycle. The stock's 52-week high is $26.18 and the 52-week low is $6.69, placing the current trading environment within a wide historical range driven by volatility in the biotech sector. The beta value of -0.20 is highly unusual for an equity security, suggesting an inverse correlation with the broader market or specific trading anomalies that must be interpreted with caution. These alternative valuation metrics collectively suggest that the market is assessing the company based on pipeline milestones and regulatory approvals rather than current financial performance.
Growth & Income
Revenue growth year-over-year is reported at 26.2%, while earnings growth year-over-year is not available due to the company's negative net income position. The absence of positive earnings growth data relative to revenue growth highlights that the company is still in a phase where top-line expansion does not yet translate to profitability, a common pattern for clinical-stage biopharmaceuticals. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividend payments is consistent with the company's strategy of reinvesting all available capital back into research, development, and clinical trials to advance its product portfolio. The overall growth and income profile is characterized by significant revenue expansion supported by substantial cash reserves, but with no current income generation for shareholders. The company's financial strategy prioritizes long-term asset creation through the Viaskin Peanut platform over immediate shareholder returns via dividends or buybacks.